Resources

In Uganda, children receive the malaria vaccine at 6 months, 7 months, 8 months, and 18 months of age. But ensuring that children complete the entire four-dose schedule presents challenges, especially for caregivers who live far from the nearest health center, are juggling responsibilities at work and at home, or lack adequate information about where and when to get their children vaccinated.To address these challenges, PATH is partnering with Communication for Development Foundation Uganda (CDFU) on a call center program that provides information to parents and other caregivers about malaria vaccination, reminders about the schedule, and referrals to vaccinating centers to ensure that children stay up to date on all four doses. This case study provides an overview of the program, which is being piloted at 60 health facilities across four districts in Uganda’s South-Central region.

The rollout of malaria vaccines represents a historic turning point in child survival across sub-Saharan Africa. Building on decades of experience, PATH provides targeted technical assistance to countries to strengthen malaria vaccine delivery within routine immunization systems and in the context of national malaria programs. This project brief provides an overview of PATH's work on malaria vaccine implementation.

This is a simple, Excel-based tool for assessing and comparing costs of pneumococcal conjugate vaccine (PCV) vaccination programs with each PCV product available in the global market. It aims to help national-level policymakers specifically in countries eligible for support from Gavi, the Vaccine Alliance, compare products and estimate vaccination program costs for different PCVs, exploring up to four different vaccine options at a time.The tool calculates cold chain volume and costs annually and for a total period of five years. Cost estimates are composed of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery). Cost estimates are provided separately for the country perspective and the combined country and Gavi perspective.It is important to note that cost is only one consideration when selecting a PCV product, and users involved in decision-making around new vaccine introduction/switch or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. The tool is available to download in multiple languages below. Please be sure to check out this seven-minute tutorial video, which is in English, with French and Spanish subtitled versions also available. If you have additional questions or need support, contact PATH’s Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the calculator, which is periodically updated to reflect the evolving vaccine landscape.

Vaccine adjuvants play a critical role in enhancing immune responses, enabling dose-sparing and fewer immunizations, and providing more durable protection. However, in low- and middle-income countries (LMICs), vaccine developers must contend with challenges such as cost restraints, limited cold-chain infrastructure, manufacturing scalability, and programmatic complexity.Intended for LMIC vaccine manufacturers, this PATH-organized two-part webinar provides an overview of vaccine adjuvants, highlighting how adjuvants can enhance immune responses and support manufacturers in addressing these region-specific vaccination challenges. Topics include adjuvant types, immunological principles and mechanisms of action, regulatory considerations, manufacturing challenges, and strategies to improve vaccine efficacy and access.The session features dialogue among researchers, vaccine manufacturers, adjuvant developers, and regulatory teams focused on the advancement, development, approval, and deployment of suitable adjuvants tailored for LMIC needs.Speakers include:Lakshmi Khandke, PhD, Senior Program Advisor, Vaccines CMC, Center for Vaccine Innovation and Access, PATHDerek O’Hagan, PhD, Head of Vaccine Adjuvants and Delivery Systems, GSKMark Alderson, PhD, CSO and US Site Director, Maxvax BiotechnologyJulie Jospeh, PhD, Senior Biologist/Evaluator, Health Canada Centre for Vaccines, Clinical Trials, and BiostatisticsDaniel Fullen, PhD, Lead, R&D Innovations, Center for Epidemic Preparedness Innovations (CEPI)Dennis Christensen, PhD, Head of Global Research and Development, Adjuvant Systems, Croda PharmaWolfgang Leitner, DSc, Chief of the Innate immunity Section of the Basic immunology Branch/Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID)Jay Evans, PhD, Co-Founder and Chief Scientific & Strategy Officer, Inimmune Corporation and Director of the Center for Translational Medicine, University of Montana

The Pandemic Fund, hosted by the World Bank, provides long-term financing to strengthen the capacities of low- and middle-income countries to prevent, detect, and respond to future pandemics. It was established in 2022 to address gaps exposed by COVID-19 and support investments in disease surveillance systems, laboratory networks, emergency response capacity, health workforce training, and One Health systems linking human, animal, and environmental health.This brief, part of a series on Global health financing for oxygen systems, is intended to support applicants, partners, civil society, and others in developing funding requests and/or advocating for prioritization of medical oxygen, pulse oximetry, and respiratory therapies in Pandemic Fund applications. It builds from previous efforts to support oxygen inclusion in Pandemic Fund proposals.